CytoDyn Inc. (CYDY): Price and Financial Metrics
CYDY Price/Volume Stats
| Current price | $0.15 | 52-week high | $0.42 |
| Prev. close | $0.15 | 52-week low | $0.13 |
| Day low | $0.13 | Volume | 1,479,740 |
| Day high | $0.15 | Avg. volume | 2,823,404 |
| 50-day MA | $0.17 | Dividend yield | N/A |
| 200-day MA | $0.19 | Market Cap | 146.95M |
CYDY Stock Price Chart Interactive Chart >
CytoDyn Inc. (CYDY) Company Bio
CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Latest CYDY News From Around the Web
Below are the latest news stories about CytoDyn Inc that investors may wish to consider to help them evaluate CYDY as an investment opportunity.
CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification ReportCompany Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission |
CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy ContestVANCOUVER, Washington, August 05, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group" or the "Activist Group"). The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control |
CytoDyn Receives Clearance from Brazils ANVISA to Commence Phase 3 Trial for Severe COVID-19 PatientsVANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazils regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organ |
CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 PatientsVANCOUVER, Washington, August 03, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organi |
CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are InvalidVANCOUVER, Washington, August 02, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group") were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the "Board"). |
CYDY Price Returns
| 1-mo | -10.13% |
| 3-mo | -18.92% |
| 6-mo | -6.19% |
| 1-year | -51.06% |
| 3-year | -95.43% |
| 5-year | -67.32% |
| YTD | -23.08% |
| 2023 | -13.33% |
| 2022 | -77.24% |
| 2021 | -81.66% |
| 2020 | 439.00% |
| 2019 | 112.77% |
Loading social stream, please wait...